Orano Med

📍 Plano, United States🗓 Founded 2009👥 97 employees💰 Last funded Sep 2022
Biotechnology Research🌐 oranomed.com
Website LinkedIn
Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope.  Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer.  The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products.  For more information please visit www.macrocyclics.com.
3
Total investors
0
Early stage
0
Mid stage
2
Late stage
2009
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography3 countries
United States
1
Canada
1
France
1
Investor activity2017–2022 · investors recorded per year
201712018120221
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Orano Med?
Orano Med has 3 investors on record on gritt.io and 2 late-stage investors.
When did Orano Med last raise funding?
The most recent investment in Orano Med recorded on gritt.io was in September 2022.
When was Orano Med founded?
Orano Med was founded in 2009.
What industry is Orano Med in?
Orano Med operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Orano Med based?
Orano Med is headquartered in Plano, United States.